Conflict of Interest Disclosures: Dr Peikert reported a research grant from the German Research Foundation. Dr Chandra reported research grant support from Palomarin (August Health). Dr Kosiborod has received research grant support from AstraZeneca, and Boehringer Ingelheim; has served as a consultant or on an advisory board for Alnylam, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Esperion Therapeutics, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Novo Nordisk, Sanofi, Pharmacosmos and Vifor Pharma; has received other research support from AstraZeneca; and has received honoraria from AstraZeneca, Boehringer Ingelheim, and Novo Nordisk as well as payments to institution from Cytokinetics, Dexcom, Pfizer, scPharmaceuticals, Structure Therapeutics, Youngene Therapeutics, and 35Pharma outside the submitted work. Dr Claggett has received consulting fees from Boehringer Ingelheim, Cardurion, Corvia, Cytokinetics, Novartis, Intellia, and Rocket outside the submitted work. Dr Desai reports institutional grant support from Abbott, Alnylam, AstraZeneca, Bayer, and Novartis; consulting fees from Abbott, Alnylam, AstraZeneca, Avidity, Axon Therapeutics, Bayer, Biofourmis, Boston Scientific, Cytokinetics, GlaxoSmithKline, Medpace, Merck, Novartis, Parexel, Regeneron, River2Renal, Roche, Verily, Veristat, and Zydus; and grants from Pfizer (to institution) outside the submitted work. Dr Jhund has received speaking fees from AstraZeneca, Novartis, Alkem Metabolics, ProAdWise Communications, Sun Pharmaceuticals; advisory board fees from AstraZeneca, Boehringer Ingelheim, Novartis; research funding from AstraZeneca, Boehringer Ingelheim, and Analog Devices Inc; grants from Analog Devices Inc; and personal fees from Roche and Intas Pharma and serves as director of Global Clinical Trial Partners (GCTP). Dr Jhund’s employer, the University of Glasgow, has been remunerated for clinical trial work from AstraZeneca, Bayer, Novartis, and NovoNordisk. Dr Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on an advisory board, steering committee, or executive committee for Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma, EchoNous, Eli Lilly, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development, Medscape/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Radcliffe Group, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as cofounder and nonexecutive director of Us2.ai. Dr Inzucchi has served on clinical trial committees or as a consultant for AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lexicon, Merck, Pfizer, vTv Therapeutics, Abbott, and Esperion; has given lectures sponsored by AstraZeneca and Boehringer Ingelheim; and has received personal fees from Bayer outside the submitted work. Dr Martinez has received personal fees from AstraZeneca. Dr de Boer has received research grant support, served on advisory boards, or had speaker engagements with AstraZeneca, Abbott, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novartis, Novo Nordisk, and Roche. Dr Hernandez has received research grants from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Somologic, and Verily and has served as a consultant or on an advisory board for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cytokinetics, Eidos, Intercept, Merck, and Novartis. Dr Shah has received research grants from the National Institutes of Health, Actelion, AstraZeneca, Corvia, Novartis, and Pfizer and has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, GSK, Intellia, Ionis, Ironwood, Eli Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Sardocor, Shifamed, Tenax, Tenaya, and United Therapeutics. Dr Janssens has received personal and institutional research support for DELIVER from AstraZeneca. Dr Bělohlávek reported lecture honoraria from AstraZeneca during the conduct of the study and consultancy fees or lecture honoraria from Novartis, Boehringer Ingelheim, Getinge, Abiomed, and Bayer outside the submitted work. Dr Borleffs served on advisory boards or had speaker engagements with Abbott, AstraZeneca, Novartis, and Boehringer Ingelheim. Dr Dobreanu reported personal fees from Bayer, Berlin Chemie, Novartis, Servier, Viatris, Vifor, Zentiva, and Sanofi outside the submitted work. Drs Langkilde, Bengtsson, and Petersson are employees and shareholders at AstraZeneca. Dr McMurray’s employer, Glasgow University, has been paid by AstraZeneca (who markets dapagliflozin) for his time spent as principal investigator of the DAPA-HF trial and coprincipal investigator of the DELIVER trial (trials using dapagliflozin) in heart failure and meetings related to the trial as well as executive committee member for the DETERMINE and PRIORITIZE trials and an advisory board member for the AZD9977 trial. AstraZeneca has also paid Dr McMurray’s travel and accommodation for related meetings. These payments were made through a consultancy with Glasgow University and Dr McMurray has not received personal payments in relation to this trial or drug. Glasgow University has also been paid by KBP Biosciences for Dr McMurray’s time spent as scientific advisor to help guide clinical development in cardio-renal disease, inflammation, and infection; by Amgen for Dr McMurray’s time spent as a steering committee member for the GALACTIC-HF trial and meetings related to this trial, and Amgen paid for Dr McMurray’s travel and accommodation for some of these meetings but no personal payments were received by Dr McMurray in to these trials or drug; by Cytokinetics for Dr McMurray’s time spent as a steering committee member for the ATOMIC-HF, COSMIC-HF, and GALACTIC-HF trials and meetings and other activities related to these trials, and Cytokinetics paid for Dr McMurray’s travel and accommodation for some of these meetings and activities but no personal payments were made to Dr McMurray in relation to these trials or drug; by Cardurion for Dr McMurray’s participation in a company advisory board about development in connection with drug development and design of clinical trials; by Bayer for Dr McMurray’s time spent as coprincipal investigator of the FINEARTS trial with finerenone, but Dr McMurray received no personal payments in relation to these trials or drugs; by GSK for Dr McMurray’s time spent as coprincipal investigator and steering committee member, respectively, for the Harmony-Outcomes trial (albiglutide) and ASCEND-D and ASCEND-ND trials using daprodustat and meetings related to these trials, and GSK paid for Dr McMurray’s travel and accommodation for some of these meetings but Dr McMurray has not received personal payments in relation to these trials or drugs; and by Novartis for Dr McMurray’s time spent as executive committee member and then coprincipal investigator of ATMOSPHERE, coprincipal investigator of the PARADIGM-HF trial, and executive/steering committee member for the PARACHUTE-HF, PARADISE-MI, and PERSPECTIVE trials (with sacubitril/valsartan) and meetings or presentations related to these trials and aliskiren and sacubitril/valsartan, and Novartis paid for Dr McMurray’s travel and accommodation for some of these meetings but Dr McMurray has not received personal payments in relation to these trials or drugs.Dr McMurray also reports personal fees from George Clinical for serving on the data safety monitoring advisory board; lecture fees from Abbott, Alkem Metabolics, AstraZeneca, Blue Ocean Scientific Solutions, Boehringer Ingelheim, Canadian Medical and Surgical Knowledge, Emcure Pharmaceuticals, Eris Lifesciences, European Academy of Continuing Medical Education, Hikma Pharmaceuticals, Imagica Health, Intas Pharmaceuticals, J.B. Chemicals & Pharmaceuticals, Lupin Pharmaceuticals, Medscape/Heart.Org., ProAdWise Communications, Radcliffe Cardiology, Sun Pharmaceuticals, The Corpus, Translation Research Group, Translational Medicine Academy; consultancy fees from Alynylam Pharmaceuticals, Bayer, Bristol Meyers Squibb, Ionis Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, River 2 Renal Corp; and other from Theracos. Dr Solomon reports research grants (paid to institution) from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Eli Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart, Lung, and Blood Institute, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and Us2.ai and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GSK, Eli Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, and Valo outside the submitted work. Dr Vaduganathan has received research grant or other support, served on advisory boards, or had speaker engagements with American Regent, Amgen, AstraZeneca, Bayer, Baxter Healthcare, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health and participates on clinical trial committees for studies sponsored by AstraZeneca, Galmed, Novartis, Bayer, Occlutech, and Impulse Dynamics outside the submitted work. No other disclosures were reported.
